Atomoxetine Use Doesn't Up Suicide Risk in Children

Share this content:
Atomoxetine Use Doesn't Up Suicide Risk in Children
Atomoxetine Use Doesn't Up Suicide Risk in Children

WEDNESDAY, April 27, 2016 (HealthDay News) -- Treatment with the selective noradrenalin-reuptake-inhibitor atomoxetine is not associated with increased suicide risk compared with stimulant use in children and adolescents, according to a study published online April 26 in Pediatrics.

Stephan Linden, Ph.D., from the University of Florida in Gainesville, and colleagues examined the risk of suicide and suicide attempt in pediatric patients initiating treatment with atomoxetine versus stimulants in a retrospective cohort design study. The first- and second-line treatment cohorts included 279,315 and 220,215 patients, respectively.

The researchers found that in the first-line treatment cohort the adjusted hazard ratio for current atomoxetine use versus stimulant use was 0.95 during the first year of follow-up (95 percent confidence interval, 0.47 to 1.92; P = 0.88). The adjusted hazard ratio for current atomoxetine use versus stimulant use was 0.71 during the first year of follow-up in the second-line treatment cohort (95 percent confidence interval, 0.30 to 1.67; P = 0.43).

"First- and second-line treatment of youths age 5 to 18 with atomoxetine compared with stimulants was not significantly associated with an increased risk of suicidal events," the authors write. "The low incidence of suicide and suicide attempt resulted in wide confidence intervals and did not allow stratified analysis of high-risk groups or assessment of suicidal risk associated with long-term use of atomoxetine."

Two authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »